The increasing prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) variants with spike protein mutations raises concerns that antibodies elicited by natural …

ABSTRACT DNA sequence analysis recently identified the novel SARS-CoV-2 variant B.
1.526 that is spreading at an alarming rate in the New York City area. Two versions of the …

The emergence of SARS-CoV-2 variants with mutations in the spike protein is raising
concerns about the efficacy of infection-or vaccine-induced antibodies. We compared …

Multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines show
protective efficacy, which is most likely mediated by neutralizing antibodies recognizing the …

Several severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants have
arisen that exhibit increased viral transmissibility and partial evasion of immunity induced by …

Neutralizing antibodies against the SARS-CoV-2 spike (S) protein are a goal of COVID-19
vaccines and have received emergency use authorization as therapeutics. However, viral …

Monoclonal antibodies against the SARS-CoV-2 spike protein, notably, those developed by
Regeneron Pharmaceuticals and Eli Lilly and Company have proven to provide protection …

All current vaccines for COVID-19 utilize ancestral SARS-CoV-2 spike with the goal of
generating protective neutralizing antibodies. The recent emergence and rapid spread of …

Mutations in the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) variants can compromise the effectiveness of therapeutic antibodies. Most clinical …

One year in the coronavirus disease 2019 (COVID-19) pandemic, the first vaccines are
being rolled out under emergency use authorizations. It is of great concern that newly …